Skip to main content

Durham's Qualyst Launches New Test for Avoiding Liver Toxicity

Durham-based Qualyst Transporter Systems (QTS) has launched a new test that can steer drug developers away from compounds that could cause liver damage.

Heat Biologics Gets Good News from Early Cancer Trial

Heat Biologics, a Durham company developing immunotherapies to fight cancer, has reported positive results from a Phase 1b trial of its combination treatment for non-small cell lung cancer.

Panaceutics Scaling up for Customized Production in Personalized Medicine, Nutrition

The Research Triangle Park-based personalized medicine and clinical nutrition company formerly known as Panacea BioMatx is quickly transforming itself in 2017.

'Synergy' Behind Heat Biologics/Pelican deal is Key to Immunology

When Heat Biologics licensed the immune system stimulating technology behind its ImPACT and ComPACT platforms from the University of Miami, it also licensed the tech behind Pelican Therapeutics Inc.

Heat Biologics Acquires Synergistic Austin-based Immune Therapy Firm

Durham-based Heat Biologics Inc. (Nasdaq:HTBX), has inked a deal to acquire an 80 percent controlling interest in Pelican Therapeutics Inc., an immune oncology company based in Austin, Texas.

HepatoSys, Lonza Collaborate on Liver Cell Research

Charlotte-based HepatoSys has received a $366,000 Phase I grant from the federal Small Business Innovation Research (SBIR) program to fund the research. It will team up with Lonza which acquired Triangle Research Labs of Research Triangle Park in June 2016 to explore HepatoSys’ patented technology for rejuvenating donated human livers that aren’t healthy enough for organ transplants.

Pfizer Commits $4M to NCBiotech Gene Therapy Fellowship Program

Pfizer has committed to providing $4 million to enable the North Carolina Biotechnology Center to establish and administer a  multi-year academic fellowship program to help advance the state's gene therapy expertise.

LabCorp CEO David P. King to Keynote Triad BioNight 2017

The North Carolina Biotechnology Center has announced that LabCorp Chairman and CEO David P. King will be the keynote speaker for the March 30 Triad BioNight 2017 gala in Greensboro.

Cempra's Skin Antibiotic Taksta Data Promising

Taksta, Cempra’s fusidic acid compound, is proving to be both safe and effective in the treatment of acute bacterial skin and skin structure infections.

Soil Health Technology Goes to Market

A venture-backed Cary-based plant health company says agricultural growers can maximize their investments with its patented biological, nutritional seed treatment and other technologies.

Pages

Subscribe to RSS - NCBiotech